Department of General Pediatrics, Neonatology and Pediatric Cardiology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University, Moorenstrasse 5, 40225 Düsseldorf, Germany.
M.A.R.C.O. GmbH & Co. KG, Institute for Clinical Research and Statistics, Schirmerstraße 71, 40211 Düsseldorf, Germany.
Eur J Pharm Biopharm. 2021 Sep;166:126-134. doi: 10.1016/j.ejpb.2021.06.007. Epub 2021 Jun 19.
There is limited evidence for the acceptability of various drug formulations holding the potential to improve medicines administration to children. Suitable formulations need to meet the requirements of pediatric patients. Previous studies have demonstrated the acceptance of mini-tablets. Oblong tablets may carry more active ingredient content per unit than mini-tablets and could be an important alternative when the drug substance requires administration of higher doses. The primary objective was to demonstrate non-inferiority of acceptability of oblong tablets in comparison to 3 ml glucose syrup in children aged 1 to 5 years. Secondary objectives were investigation of acceptability, swallowability and palatability of mini-tablets, oblong tablets and glucose syrup in children between 1 and 5 years.
An open, randomized, single dose two-way cross-over design in two parallel study arms was applied. 280 children were stratified to one of five age groups and randomized to receiving one oblong tablet (2.5 × 6 mm) in comparison either to 3 ml glucose syrup or to three mini-tablets (2 × 2 mm). Acceptability and swallowability were assessed according to pre-defined evaluation criteria. The application of the formulations was video documented to evaluate the palatability.
As primary objective, non-inferiority was observed regarding acceptability of the oblong tablet compared to syrup in all age groups (84.4% vs 80.1%, difference 4,29% points with 95% CI of -3.00%,11.57%). For swallowability, superiority of the oblong tablet compared to syrup could be shown (74.5% vs. 53.2%, difference 21.26% points, 95% CI of 11.29%, 31.23%). Regarding palatability, <10% of children demonstrated unpleasant reaction after intake of the oblong tablet or mini-tablets as graded by both raters, however, in contrast up to 40% of children after intake of syrup.
Oblong tablets are a promising, safe alternative to liquid drug formulations and administration of multiple mini-tablets in children.
目前,仅有有限的证据可以证明各种具有改善儿童用药管理潜力的药物制剂的可接受性。合适的制剂需要满足儿科患者的需求。先前的研究已经证明了迷你片剂的可接受性。长方型片剂每单位可能含有比迷你片剂更多的活性成分,并且当药物物质需要更高剂量给药时,它可能是一种重要的替代选择。主要目标是证明在 1 至 5 岁儿童中,长方型片剂与 3 毫升葡萄糖浆相比具有非劣效性。次要目标是调查 1 至 5 岁儿童迷你片剂、长方型片剂和葡萄糖浆的可接受性、可吞咽性和口感。
采用开放、随机、单剂量、两向交叉设计,分为两个平行研究组。280 名儿童按年龄分为五组之一,并随机分为接受一片长方型片剂(2.5×6 毫米),分别与 3 毫升葡萄糖浆或三片迷你片剂(2×2 毫米)比较。根据预先定义的评估标准评估可接受性和可吞咽性。制剂的应用通过视频记录来评估口感。
作为主要目标,在所有年龄组中,长方型片剂与糖浆相比,可接受性均观察到非劣效性(84.4%对 80.1%,差异 4.29%点,95%CI-3.00%,11.57%)。对于可吞咽性,长方型片剂与糖浆相比具有优越性(74.5%对 53.2%,差异 21.26%点,95%CI11.29%,31.23%)。关于口感,<10%的儿童在摄入长方型片剂或迷你片剂后表现出不愉快的反应,而<10%的儿童在摄入糖浆后表现出不愉快的反应,<10%的儿童在摄入糖浆后表现出不愉快的反应,<10%的儿童在摄入糖浆后表现出不愉快的反应,<10%的儿童在摄入糖浆后表现出不愉快的反应。
长方型片剂是一种有前途的、安全的替代液体药物制剂和在儿童中多次给予迷你片剂的方法。